What Xcenda does

Xcenda is a strategic consultancy operating as the market access and commercialization support brand within Cencora, Inc. (formerly AmerisourceBergen, NYSE: COR). Founded in 1994 and headquartered in Palm Harbor, Florida, the firm employs between 501 and 1,000 people and provides biopharma manufacturers with services spanning market access strategy, health technology assessment (HTA) readiness, health economics and outcomes research (HEOR), reimbursement and policy consulting, value and access strategy, early access programs, lifecycle management, training and learning solutions, and creative services. Delivery is supported by a bench of 550+ market access experts across 50+ countries with 30+ years of product-launch experience across disease states and patient populations, and is extended regionally through sub-brands NeoHealthHub (Europe and United States) and Innomar Strategies (Canada).

The underlying technology stack is not disclosed at the Xcenda standalone level, and there are no public APIs, SDKs, or mobile applications; capability delivery is built around human expertise, advisory panels, the Managed Care Network (MCN) Forum, payer discussion groups, and the Dymaxium-acquired evidence and data assets. Xcenda makes money through professional services engagements priced on a quote basis, sold via an enterprise field-sales motion that targets both large established biopharma manufacturers and emerging biopharma brands from pre-launch through product maturity, leveraging Cencora's broader distribution, logistics, and patient access ecosystem to offer bundled commercialization support across the product lifecycle.

Name

Xcenda

Legal name

Cencora, Inc.

Website

https://xcenda.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Xcenda is a Cencora-owned strategic consultancy that provides market access, HEOR, reimbursement, and commercialization consulting to large and emerging biopharma manufacturers, delivered by 550+ experts across 50+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Palm Harbor

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Consulting and Advisory Services: Revenue generated through professional consulting engagements for market access strategy, health economics outcomes research (HEOR), regulatory affairs, and commercialization support services provided to biopharma manufacturers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Xcenda is a strategic consulting firm that provides market access strategy, health economics and outcomes research (HEOR), reimbursement and policy consulting, and end-to-end commercialization support services for biopharma manufacturers. Its offerings span pre-launch through product maturity, including value and access strategy, early access programs, life cycle management, creative services, and customized training solutions, delivered by a team of more than 550 market access experts across 50+ countries.

Product overview

Xcenda, part of Cencora, offers a comprehensive suite of market access and commercialization support services organized as an integrated platform. The core services include Market Access Consulting, Reimbursement and Policy Consulting, Value and Access Strategy, and Strategy, Tools, and Testing. These are supported by additional modules including Creative Services, Training and Learning Solutions, Early Access Programs, and Life Cycle Management and Retention. The offering is enhanced by affiliated sub-brands NeoHealthHub (providing commercialization services in Europe and the United States) and Innomar Strategies (providing market access services in Canada). The platform leverages a team of over 550 market access experts across 50+ countries with 30+ years of experience launching products across various disease states and patient populations, enabling clients to translate data into credible evidence, achieve faster speed-to-market, and differentiate products in crowded marketplaces.

Differentiator

Problem solved

Functional benefit

Products and services

• Market Access Consulting Expert guidance for market access, market research, health technology assessment (HTA) readiness, and health outcomes and economics research (HEOR) to improve chances for successful product launch for biopharma manufacturers.
• Reimbursement and Policy Consulting Expert guidance for navigating the complex landscape of healthcare reimbursement and policy, helping build comprehensive reimbursement and launch strategy to maximize commercial success for biopharma manufacturers.
• Value and Access Strategy Product differentiation by defining and communicating value to stakeholders, engaging with payers and formulary decision makers for strategic feedback through market research and payer insights, targeted at biopharma manufacturers.
• Strategy, Tools, and Testing Identification, demonstration, and communication of a product's clinical and economic value, leveraging advisory panels and gaining insights into value propositions, reimbursement barriers, and market dynamics for biopharma manufacturers.
• Creative Services Brand identity and multi-component campaign development including logo design, booth design, web design, and training materials to support product storytelling for biopharma manufacturers.
• Training and Learning Solutions Customized eLearning courses and training programs designed for field application, transforming scientific evidence and market intelligence into easily absorbable content for biopharma sales and field teams.
• Early Access Programs Expertise and support for creating effective early access programs during the pre-launch period, navigating complex regulated processes with logistics guidance and support for biopharma manufacturers.
• Life Cycle Management and Retention Comprehensive loss of exclusivity (LOE) strategic planning, pricing strategy evaluation when generic competitors enter the market, and product lifecycle management at every stage for biopharma manufacturers.
• NeoHealthHub Commercialization services offered in Europe and the United States, including logistics, warehousing, and global pharma services, delivered as a related solution alongside Xcenda's market access offerings.
• Innomar Strategies Market access services offered in Canada, including consulting services for the Canadian pharmaceutical market, delivered as a related solution alongside Xcenda's market access offerings.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• NeoHealthHubcoreChannel Partner/ Reseller/ DistributorNeoHealthHub is a related solution offering commercialization services in Europe and the United States. It provides logistics and warehousing services alongside market access support for pharma manufacturers in these regions.
• Innomar StrategiescoreChannel Partner/ Reseller/ DistributorInnomar Strategies offers market access services in Canada, providing consulting services to support pharma market access and commercialization in the Canadian market.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• IQVIA: IQVIA is the largest life sciences consulting and data services firm, directly competing with Xcenda across market access, HEOR, and commercialization strategy for biopharma manufacturers, with a much broader analytics and technology platform.
• Parexel International: Parexel is a global biopharma services firm offering market access, HEOR, and commercialization strategy alongside clinical development — overlapping with Xcenda on access and evidence work for biopharma manufacturers.
• McKinsey & Company (Pharma Practice): McKinsey's Pharma & Medical Products practice provides strategy and market access consulting to the largest biopharma manufacturers, competing with Xcenda at the high end of the engagement market.

Direct peers

• Evidera: Evidera (part of Thermo Fisher/PPD) provides HEOR, market access, and real-world evidence services to biopharma, overlapping directly with Xcenda's value-and-access-strategy and HEOR offerings.
• ZS Associates: ZS Associates is a management consulting firm with a deep pharma practice in market access, launch strategy, and sales/marketing effectiveness — directly comparable to Xcenda's commercialization consulting services.
• Trinity Life Sciences: Trinity Life Sciences provides market access, evidence, and commercial strategy services to biopharma, overlapping with Xcenda on payer insights, value communication, and launch readiness.
• Syneos Health: Syneos Health offers biopharma commercialization services including consulting, medical affairs, and contract sales — competing with Xcenda on integrated launch and market access support.
• Charles River Associates: CRA's Life Sciences practice provides strategy consulting in pricing, market access, and HEOR, directly overlapping with Xcenda's economic and strategic advisory work for biopharma clients.
• Putnam Associates: Putnam Associates is a specialized pharma and biotech strategy consultancy focused on market access, launch, and commercial strategy — comparable in scope and client base to Xcenda.
• Huron Consulting Group: Huron provides healthcare and life sciences consulting including market access and reimbursement strategy, competing with Xcenda on biopharma commercialization engagements.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/xcenda
• Facebookfacebook.com/Cencora
• LinkedInlinkedin.com/company/xcenda
• Instagraminstagram.com/cencoraglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xcenda